ADVI Health is Attending Access Forum US

Join us at this year’s Access US in Austin, TX, from June 8 – June 10.

ADVI Health’s CEO, Marc Samuels, JD, MPH, Head of Policy, Research, and Analysis, Lindsay Bealor Greenleaf, JD, MBA, Senior Director, Federal Agency Engagement and Co-Lead of ADVI’s Inflation Reduction Act (IRA) Center of Excellence), John Coster, PhD, RPh, Director of Policy, Cell and Gene Therapy, Alicia Silver, MPP, Head of Business Development, Ben Shand, and Director of Federal and State Policy, Allison Schneider, will be attending to meet with clients throughout the event.

Join the Conversation

Pre-conference Short Course: Update on U.S. Medication Access and Pricing Issues: Inflation Reduction Act (IRA) and State Prescription Drug Availability Boards (PDABs)
On Sunday, June 8 at 2:00 PM, ADVI Health’s Lindsay Greenleaf, Allison Schneider, and John Coster will lead an interactive workshop on the IRA’s key provisions, including their intent, opportunities, and challenges. In this panel, they will discuss significant changes to Medicare Part D, government pricing dynamics, and state-level drug pricing initiatives. They will also dive into dual perspectives from CMS and the industry on implementing strategies to address these impacts on patient access, providers, and industry.
Plenary 2: Trump 2.0 – Key Priorities of the New Administration and What’s Next
On Monday, June 9 at 4:15 PM, ADVI Health experts will join a panel discussion on how patient access may be impacted as Trump

Administration policy shifts from campaign rhetoric

to early action in the first 100 days. Topics include signals

on deregulation, price transparency, Medicare Advantage

expansion, and potential modifications to the IRA drug

pricing provisions and MFP implementation.
Lessons Commercializing Cell and Gene Therapies with Payers

On Tuesday, June 10 at 2:15 PM, ADVI Health’s Alicia Silver will join a panel discussion on cell and gene therapies to discuss patient access, treating diseases once thought untreatable, and more.